<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012517</url>
  </required_header>
  <id_info>
    <org_study_id>0447-13-SMC</org_study_id>
    <nct_id>NCT02012517</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Prosthetic Breast Reconstructions</brief_title>
  <official_title>Antibiotic Prophylaxis in Prosthetic Breast Reconstructions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The added benefit of prolonged antibiotic prophylactic treatment in patients undergoing
      breast reconstruction who have drains placed for several days after surgery is
      controversial. In this study we aim to compare two prophylactic regimens: 1. 24 hour
      antibiotic treatment prior to surgery with cefazolin 2. a prolonged antibiotic regimen
      consisting of 48 hours cefazolin treatment followed by oral therapy with cephalexin until
      the removal of the drains. Patients will sign an informed consent form prior to the surgery
      and will be randomized to one of the antibiotic regimens. Patients will be closely followed
      up to one year after surgery. The number of surgical site infections according to the NNIS
      criteria and loss of breast implants will be compared between the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>surgical site infection</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage and number of surgical site infections assessed according to the NNIS criteria up to one year after reconstructive breast surgery will be compared between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Surgical Site Infections</condition>
  <arm_group>
    <arm_group_label>short antibiotic course</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged antobiotic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolonged antibiotic treatment</intervention_name>
    <arm_group_label>Prolonged antobiotic treatment</arm_group_label>
    <other_name>Intravenous cefazolin 2 grams every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short antibiotic course (standard of care)</intervention_name>
    <arm_group_label>short antibiotic course</arm_group_label>
    <other_name>Intravenous cefazolin 2 grams every 8 hours for 24 hours starting at surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All criteria should be present:

          1. Signing an informed consent form

          2. Reconstructive breast surgery

          3. One drain or more remained after surgery -

        Exclusion Criteria:

        Age &lt; 18 years Active infection at the surgical site at the operation time or in close
        proximity to the surgical site Immune deficiency state

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasmin Maor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmin Maor, MD</last_name>
    <email>yasmin.maor@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of plastic surgery, Sheba medical center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Yasmin Maor</investigator_full_name>
    <investigator_title>Head of the infectious didease service to the hospitalized patient, infectious disease unit</investigator_title>
  </responsible_party>
  <keyword>surgical site infection</keyword>
  <keyword>breast reconstruction</keyword>
  <keyword>drains</keyword>
  <keyword>prophylaxis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
